/TSHA
TSHA Stock - Taysha Gene Therapies, Inc.
Healthcare|BiotechnologyNASDAQ
$5.49+0.73%
+$0.04 (+0.73%) • Dec 19
86
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.79
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+97.3%upside
Target: $10.83
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TSHA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.44 – $5.54
TARGET (TP)$10.83
STOP LOSS$5.05
RISK/REWARD1:12.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.04
52W High$5.95
52W Low$1.05
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $8.33M | $15.45M | $2.50M | N/A | N/A |
| Gross Profit | $8.33M | $15.45M | $14,999 | N/A | $-9,000 |
| Gross Margin | 100.0% | 100.0% | 0.6% | N/A | N/A |
| Operating Income | $-91,459,000 | $-72,439,000 | $-126,027,000 | $-173,267,000 | $-43,002,000 |
| Net Income | $-89,298,000 | $-111,566,000 | $-166,014,000 | $-174,523,000 | $-43,000,000 |
| Net Margin | -1071.6% | -722.1% | -6635.3% | N/A | N/A |
| EPS | $-0.36 | $-0.96 | $-3.78 | $-4.64 | $-3.40 |
Company Overview
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Visit WebsiteRating Distribution
Strong Buy
1
17%
Buy / Outperform
2
33%
Hold / Neutral
3
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
3 Bullish3 Neutral/Bearish
Price Targets
$6
Average Target
↑ 10.6% Upside
Now
$2
Low
$6
Average
$13
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 21st 2025 | Raymond James | Initiation | Strong Buy | $13 |
| July 11th 2025 | BofA Securities | Initiation | Buy | $8 |
| June 27th 2024 | BMO Capital Markets | Initiation | Outperform | $5 |
| April 9th 2024 | Piper Sandler | Initiation | Overweight | $9 |
| February 1st 2023 | Jefferies | Downgrade | Hold | $1.5← $14 |
| January 27th 2023 | Morgan Stanley | Downgrade | Equal Weight | $3← $23 |
| November 9th 2022 | Goldman | Downgrade | Neutral | $3← $16 |
Earnings History & Surprises
TSHABeat Rate
39%
Last 18 quarters
Avg Surprise
+15.6%
EPS vs Estimate
Beats / Misses
7/8
3 met exactly
Latest EPS
$-0.09
Q4 2025
EPS Surprise History
Q1 24
+488.9%
$0.35vs$-0.09
Q2 24
+9.1%
$-0.10vs$-0.11
Q3 24
+10.0%
$-0.09vs$-0.10
Q4 24
-12.5%
$-0.09vs$-0.08
Q1 25
+12.5%
$-0.07vs$-0.08
Q2 25
0.0%
$-0.08vs$-0.08
Q3 25
-28.6%
$-0.09vs$-0.07
Q4 25
0.0%
$-0.09vs$-0.09
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.11 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.09 | $-0.09 | 0.0% | = MET |
Q3 2025 | Aug 12, 2025 | $-0.07 | $-0.09 | -28.6% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.08 | $-0.08 | 0.0% | = MET |
Q1 2025 | Feb 26, 2025 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.08 | $-0.09 | -12.5% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.10 | $-0.09 | +10.0% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.11 | $-0.10 | +9.1% | ✓ BEAT |
Q1 2024 | Mar 19, 2024 | $-0.09 | $0.35 | +488.9% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.13 | $-0.13 | 0.0% | = MET |
Q3 2023 | Aug 14, 2023 | $-0.31 | $-0.38 | -22.6% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.35 | $-0.28 | +20.0% | ✓ BEAT |
Q1 2023 | Mar 28, 2023 | $-0.41 | $-0.99 | -141.5% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.89 | $-0.64 | +28.1% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-1.05 | $-0.84 | +20.0% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-1.04 | $-1.31 | -26.0% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-1.21 | $-1.32 | -9.1% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-1.02 | $-1.35 | -32.4% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-0.81 | $-1.09 | -34.6% | ✗ MISS |
Latest News
Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset
📈 PositiveSeeking Alpha•Dec 4, 2025, 05:42 PM
Citizens Maintains Market Outperform on Taysha Gene Therapies, Raises Price Target to $8
📈 PositiveBenzinga•Nov 5, 2025, 12:51 PM
Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $12 Price Target
📈 PositiveBenzinga•Nov 5, 2025, 12:40 PM
Taysha Gene Therapies Q3 EPS $(0.09), Inline. Revenue $0.
➖ NeutralBenzinga•Nov 4, 2025, 11:58 AM
Raymond James Initiates Coverage On Taysha Gene Therapies with Strong Buy Rating, Announces Price Target of $13
📈 PositiveBenzinga•Oct 21, 2025, 05:43 PM
Taysha Gene Therapies regains full rights to TSHA-102
📈 PositiveSeeking Alpha•Oct 17, 2025, 02:07 PM
Needham Reiterates Buy on Taysha Gene Therapies, Maintains $10 Price Target
📈 PositiveBenzinga•Oct 17, 2025, 10:37 AM
Taysha Gene Therapies Regains Full Rights To Its Lead TSHA-102 Program In Clinical Evaluation For Rett Syndrome; TSHA-102 Has Demonstrated Compelling Part A REVEAL Phase 1/2 Safety And Efficacy Data, Received FDA Breakthrough Therapy Designation And Is Advancing With A Clear Path To Potential Registration
📈 PositiveBenzinga•Oct 16, 2025, 08:06 PM
Taysha Gene Announces Results From Supplemental Data Analysis From Part A Of REVEAL Phase 1/2 Adult/Adolescent And Pediatric Trials Evaluating TSHA-102 In Females With Rett Syndrome At CNS Annual Meeting
➖ NeutralBenzinga•Oct 9, 2025, 12:04 PM
Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $12
📈 PositiveBenzinga•Oct 2, 2025, 05:52 PM
Needham Maintains Buy on Taysha Gene Therapies, Raises Price Target to $10
📈 PositiveBenzinga•Oct 2, 2025, 02:51 PM
Taysha soars on FDA breakthrough therapy status for lead asset
📈 PositiveSeeking Alpha•Oct 2, 2025, 02:13 PM
Taysha Gene Therapies are trading higher after the FDA granted the company Breakthrough Therapy designation to TSHA-102 for the treatment of Rett syndrome.
📈 PositiveBenzinga•Oct 2, 2025, 01:25 PM
FDA Grants Breakthrough Therapy Designation To Taysha Gene Therapies' TSHA-102 For Rett Syndrome; On Track To Begin Patient Enrollment In Q4 2025
📈 PositiveBenzinga•Oct 2, 2025, 12:03 PM
Frequently Asked Questions about TSHA
What is TSHA's current stock price?
Taysha Gene Therapies, Inc. (TSHA) is currently trading at $5.49 per share. The stock has moved +0.73% today.
What is the analyst price target for TSHA?
The average analyst price target for TSHA is $10.83, based on 1 analyst.
What sector is Taysha Gene Therapies, Inc. in?
Taysha Gene Therapies, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TSHA's market cap?
Taysha Gene Therapies, Inc. has a market capitalization of $1.44 billion, making it a small-cap company.
Does TSHA pay dividends?
No, Taysha Gene Therapies, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANAB
AnaptysBio, Inc.
$49.08
Mkt Cap: $1.4B
ATAI
Atai Beckley N.V
$3.96
Mkt Cap: $0.7B
BBOT
BridgeBio Oncology Therapeutics Inc.
$12.52
Mkt Cap: $1.0B
DNTH
Dianthus Therapeutics, Inc.
$42.44
Mkt Cap: $1.5B
ELVN
Enliven Therapeutics, Inc.
$16.87
Mkt Cap: $1.0B
IMTX
Immatics N.V.
$10.27
Mkt Cap: $1.2B
NKTR
Nektar Therapeutics
$46.84
Mkt Cap: $1.0B
OCS
Oculis Holding AG
$21.25
Mkt Cap: $1.1B
SANA
Sana Biotechnology, Inc.
$4.36
Mkt Cap: $1.2B
XNCR
Xencor, Inc.
$15.55
Mkt Cap: $1.1B
Explore stocks similar to TSHA for comparison